Evaluating of the Safety, Pharmacokinetics and Pharmacodynamics of QL1205 and Lucentis® in Patients With Wet AMD
Status:
Completed
Trial end date:
2019-04-02
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, two-group parallel, positive-controlled clinical Phase I
trial comparing the safety, pharmacokinetics and pharmacodynamics of QL1205 and Lucentis® in
patients with wet age-related macular degeneration.